Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-08-01
|
| Series: | Ophthalmology and Therapy |
| Online Access: | https://doi.org/10.1007/s40123-023-00788-9 |
| _version_ | 1797736410666500096 |
|---|---|
| author | Yasuo Yanagi Kanji Takahashi Tomohiro Iida Fumi Gomi Junko Morii Eriko Kunikane Taiji Sakamoto |
| author_facet | Yasuo Yanagi Kanji Takahashi Tomohiro Iida Fumi Gomi Junko Morii Eriko Kunikane Taiji Sakamoto |
| author_sort | Yasuo Yanagi |
| collection | DOAJ |
| first_indexed | 2024-03-12T13:13:25Z |
| format | Article |
| id | doaj.art-69898440c1b84610abdd8d9fb5086f10 |
| institution | Directory Open Access Journal |
| issn | 2193-8245 2193-6528 |
| language | English |
| last_indexed | 2024-03-12T13:13:25Z |
| publishDate | 2023-08-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Ophthalmology and Therapy |
| spelling | doaj.art-69898440c1b84610abdd8d9fb5086f102023-08-27T11:11:49ZengAdis, Springer HealthcareOphthalmology and Therapy2193-82452193-65282023-08-011252821282210.1007/s40123-023-00788-9Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in JapanYasuo Yanagi0Kanji Takahashi1Tomohiro Iida2Fumi Gomi3Junko Morii4Eriko Kunikane5Taiji Sakamoto6Department of Ophthalmology and Microtechnology, Yokohama City UniversityDepartment of Ophthalmology, Kansai Medical UniversityDepartment of Ophthalmology, Tokyo Women’s Medical University School of MedicineDepartment of Ophthalmology, Hyogo Medical UniversityIQVIA Solutions Japan, K.K.Senju Pharmaceutical Co., Ltd.Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Scienceshttps://doi.org/10.1007/s40123-023-00788-9 |
| spellingShingle | Yasuo Yanagi Kanji Takahashi Tomohiro Iida Fumi Gomi Junko Morii Eriko Kunikane Taiji Sakamoto Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan Ophthalmology and Therapy |
| title | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_full | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_fullStr | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_full_unstemmed | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_short | Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan |
| title_sort | correction cost effectiveness analysis of ranibizumab biosimilar for neovascular age related macular degeneration in japan |
| url | https://doi.org/10.1007/s40123-023-00788-9 |
| work_keys_str_mv | AT yasuoyanagi correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT kanjitakahashi correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT tomohiroiida correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT fumigomi correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT junkomorii correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT erikokunikane correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan AT taijisakamoto correctioncosteffectivenessanalysisofranibizumabbiosimilarforneovascularagerelatedmaculardegenerationinjapan |